山東藥玻(600529.SH):2024年將繼續推進募投項目投產進度 適時擴充中硼硅藥用玻璃業務的產能
格隆匯1月26日丨山東藥玻(600529.SH)近日在接待機構投資者調研時表示,受一致性評價和集採的驅動,中硼硅模製瓶23年保持較快的增長速度,從前三個季度看,中硼硅模製瓶在收入端和利潤端貢獻率持續擴大。2024年公司將繼續推進募投項目的投產進度,根據市場需求,適時擴充中硼硅藥用玻璃業務的產能。
23年公司棕色瓶、日化食品瓶也有較好增長,對公司整體收入貢獻較大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.